What were the key takeaways from Jazz Pharmaceuticals’s earnings call?

What does Jazz Pharmaceuticals do and what are its main business segments?

What were the key takeaways from Jazz Pharmaceuticals's earnings call?

What is Jazz Pharmaceuticals's latest dividend and current dividend yield?

Did Jazz Pharmaceuticals beat or miss consensus estimates last quarter?

What guidance did Jazz Pharmaceuticals's management provide for the next earnings period?

What factors drove the changes in Jazz Pharmaceuticals's revenue and profit?

What is the revenue and EPS growth rate for Jazz Pharmaceuticals year over year?

- **Revenue Milestone**: 2025 total revenue of $4.3B, Q4 record $1.2B (+10% YoY), driven by rare oncology and new launches.
- **Pipeline Success**: Zanidatamab Phase III data shows 2+ years OS in GEA; Modeyso generates $48M in 8 months.
- **Financial Health**: Strong cash ($2.4B), 2026 guidance for $4.25B-$4.5B revenue, 90-91% gross margin.
- **Strategic Moves**: Sold priority voucher for $100M, resolved litigation extending patent runway, and investing $725M-$775M in R&D.

**【CEO Summary Section】**
- **Record Revenue Growth**: Total 2025 revenue reached $4.3 billion, with Q4 revenue of $1.2 billion, up 10% YoY. Key drivers included Modeyso ($48M launched in 8 months) and Zepzelca's first-line approval.
- **Strategic Acquisitions & Pipeline Expansion**: Acquired Chimerix to gain Modeyso, sold a priority review voucher for $100M, and advanced zanidatamab with Phase III data showing 2+ years OS in GEA.
- **Litigation Resolution**: Settled Epidiolex ANDA litigation, extending patent runway to late 2030s, and resolved rare disease franchise litigation.
- **Rare Disease Focus**: Shifted strategy to rare disease, leveraging expertise in epilepsy, narcolepsy, and oncology. Zanidatamab's potential in breast cancer and GEA is a key growth driver.

**【CFO Financial Commentary】**
- **2025 Financials**: Non-GAAP net income of $522M, EPS of $8.38. Full-year revenue growth of 5%, driven by rare oncology (+20%) and epilepsy (+9%).
- **2026 Guidance**: Total revenue $4.25B-$4.5B (midpoint +2.5%). Rare oncology to grow double-digit, sleep franchise expected decline due to generics. Gross margin 90-91%, R&D spend $725M-$775M for zanidatamab and pipeline.
- **Balance Sheet Strength**: $2.4B cash, strong operating cash flow ($1.4B). Tax rate 11.5-13.5% due to deferred tax asset.

**【Q&A Highlights】**
- **Xywav Competition**: Flat to mid-single-digit growth expected in 2026, with minimal impact from generics in H1. IH patient adds (+34% in 2025) and low sodium differentiation mitigate risk.
- **Modeyso Launch**: $48M in 2025, targeting >$500M peak. ACTION trial OS readout mid-2026 could expand use to first-line post-radiation.
- **Zanidatamab in Breast Cancer**: Phase III trial (550 pts) comparing to Herceptin, with PFS and OS endpoints. Mid-2027 readout for metastatic breast cancer trial.
- **Balance Sheet Strategy**: Leverage at 1.5x EBITDA, open to M&A but focused on deleveraging over time.

Jazz Pharmaceuticals plc(JAZZ)-20260225-2025 Q4 Earnings call transcript

- **Revenue Record**: Q3 2025 revenue of $1.126B (+7% YoY), driven by sleep, epilepsy, and oncology growth.
- **FDA Wins**: Zepzelca first-line approval and Modeyso launch highlight regulatory momentum.
- **Pipeline Catalysts**: Zanidatamab GEA data due Q4, Kv7 epilepsy deal expands early-stage pipeline.
- **Generic Risk**: 2026 Xyrem generics expected, but Xywav's low-sodium differentiation and Hikma royalties mitigate impact.
- **Financial Strength**: $2B cash, narrowed 2025 guidance to $4.175B–$4.275B, and strong cash flow support growth.

**【CEO Summary Section】**
- **Record Revenue**: Q3 2025 revenue reached $1.126 billion, up 7% YoY, driven by strong performance across sleep, epilepsy, and oncology portfolios.
- **FDA Milestones**: Secured FDA approvals for Zepzelca in first-line maintenance therapy for small cell lung cancer and Modeyso for recurrent diffuse midline glioma. Both treatments were included in NCCN Guidelines.
- **Pipeline Progress**: Zanidatamab Phase III trial in gastroesophageal adenocarcinoma (GEA) expected to report top-line data later in Q4. Acquired Saniona's Kv7.2/3-selective inhibitor for epilepsy, expanding early-stage pipeline.
- **Litigation Resolution**: Settled all Xyrem antitrust and Avadel litigation, reducing legal uncertainties and enabling strategic focus.
- **Revenue Guidance**: Narrowed 2025 revenue guidance to $4.175 billion–$4.275 billion, reflecting confidence in execution.

**【CFO Financial Commentary】**
- **Q3 Financials**: Adjusted net income of $501 million, with ANI boosted by $0.66 per share from deferred tax assets and litigation settlements.
- **Revenue Breakdown**: Sleep portfolio ($520M, +7%), epilepsy ($303M, +20%), oncology ($179M, -8%), and new products (Modeyso: $11M) drove growth.
- **Cost Management**: Strong cash flow ($998M for 9M 2025) and balance sheet ($2B in cash), supporting R&D and M&A.
- **Guidance Adjustments**: Reduced R&D and SG&A due to portfolio optimization and lower litigation costs.

**【Commercial Highlights】**
- **Xywav**: $431M in net sales (+11% YoY), 450 net patient adds, and 10% volume growth. Facing potential generic competition in 2026, but differentiation via low sodium and IH exclusivity maintained.
- **Epidiolex**: $303M (+20% YoY), 10% volume growth, and/blockbuster status on track. Refinement of U.S. accruals boosted Q3 revenue.
- **Modeyso**: $11M in first 2 weeks post-launch, 200+ patients treated, and rapid uptake in ultra-rare glioma.
- **Zepzelca**: $79M (-8% YoY) due to competitive dynamics, but new first-line indication poised for growth.

**【Pipeline & R&D】**
- **Zanidatamab**: HERIZON-GEA trial updated to ITT PFS analysis (920 pts) and OS interim in Q4. Fully enrolled with 50%+ enrollment in ACTION trial for diffuse glioma.
- **Kv7.2/3 Inhibitor**: Licensing deal with Saniona for epilepsy, targeting nonselective Kv7 limitations.
- **Dordaviprone**: NDA submission for diffuse glioma expected in H1 2026, with 95+ sites enrolled.

**【Q&A Highlights】**
- **Generic Xyrem**: 2026 entry could disrupt Xywav, but Jazz maintains low-sodium differentiation and royalty participation via Hikma agreement.
- **Orexin Agonists**: Xywav's sleep architecture benefits (DUET study) position it as complementary to wake-promoters, not direct competitors.
- **Zanidatamab Pricing**: GEA launch expected to align with BTC pricing, leveraging existing infrastructure.
- **Kv7 Pipeline**: Best-in-class specificity for epilepsy, with IND filing planned in 2026.

Jazz Pharmaceuticals plc (JAZZ) Q3 2025 Earnings Call Transcript

- **CEO Transition & Growth**: Renee Gala as CEO to drive innovation, with Q2 revenue $1.05B (+2% YoY) led by 13% Xywav growth.
- **Pipeline Momentum**: Zepzelca first-line maintenance PDUFA Oct 7, dordaviprone PDUFA Aug 18, zanidatamab GEA readout Q4.
- **Financial Resilience**: $519M operating cash flow, $1.7B cash, revised 2025 revenue $3.9-4.0B.
- **Oncology Recovery**: Zepzelca poised for rebound with first-line data; dordaviprone launch prep underway.
- **Blockbuster Potential**: Epidiolex on track for $1B+ annual sales despite inventory challenges.

**【CEO Summary Section】**
- Announced Renee Gala as CEO, emphasizing her leadership in driving growth and innovation.
- Highlighted progress across commercial, R&D, and corporate development, including the Chimerix acquisition and dordaviprone's upcoming FDA decision.
- Q2 2025 total revenue of $1.05 billion, with Xywav growing 13% YoY and Epidiolex on track for blockbuster status.
- Oncology portfolio faced near-term headwinds but positioned for growth with Zepzelca's first-line maintenance PDUFA and dordaviprone launch.

**【COO Commercial Performance】**
- Xywav net sales $415M (+13% YoY), driven by 625 net patient adds across narcolepsy and IH, with IH adds up 400Q.
- Epidiolex net sales $252M (+2% YoY), impacted by U.S. inventory dynamics but strong demand globally.
- Oncology products (Rylaze, Zepzelca, Ziihera) down 1% YoY due to competitive pressures and protocol changes.

**【CFO Financial Commentary】**
- Q2 2025 adjusted net loss $505M due to $905M non-deductible IPR&D charge from Chimerix.
- Operating cash flow $519M for first half, with $1.7B cash balance post-acquisition.
- Revised 2025 guidance: Revenue $3.9-4.0B (midpoint -4%), SG&A down 10-12%, R&D down 15-17%.

**【CMO Pipeline Update】**
- Zepzelca sNDA for first-line maintenance in SCLC with PDUFA Oct 7; IMforte data shows 46% PFS improvement vs. atezolizumab alone.
- Zanidatamab Phase III GEA readout expected late Q4; Phase II breast cancer trial initiated.
- Dordaviprone NDA for recurrent H3 K27M-mutant glioma with PDUFA Aug 18; ACTION trial enrolling frontline patients.

**【Q&A Highlights】**
- Xywav IH growth sustainability supported by digital campaigns and field nurse educators.
- Zepzelca facing competition from tarlatamab but poised for growth with first-line maintenance approval.
- Dordaviprone launch preparedness with dedicated team and 2037+ patent life.
- Epidiolex on track for $1B+ annual sales despite inventory headwinds.
- Ziihera BTC feedback positive, with GEA trial data awaited.


Jazz Pharmaceuticals plc (JAZZ) Q2 2025 Earnings Call Transcript

- **Neuroscience Dominance**: Xywav (+9%) and Epidiolex (+10%) drive 5% YoY revenue growth, IH market expansion via digital campaigns.
- **Oncology Turnaround**: Zepzelca 1st-line maintenance SNDA submitted, Dordaviprone NDA with Aug 2025 PDUFA date. Rylaze normalization expected Q2.
- **Pipeline Momentum**: Zanidatamab Phase III GEA readout Q3, Dordaviprone targeting rare glioma with 2037 patent. JZP441 type 1 narcolepsy trial initiated.
- **Financial Resilience**: $4.15B-$4.4B 2025 guidance, tariff mitigation via U.S. manufacturing, $224M GAAP net income despite $172M litigation charge.

**【CEO Opening Remarks】**
- Q1 2025 total revenue: $898M, driven by 9% YoY growth in Xywav and 10% in Epidiolex.
- Oncology portfolio impacted by Rylaze protocol changes, but poised for recovery with Zepzelca expansion and Dordaviprone NDA submission.
- Acquired Chimerix to strengthen rare oncology presence, with Dordaviprone targeting H3K27M-mutant diffuse glioma.

**【Commercial Performance】**
- **Neuroscience**: Xywav (narcolepsy/IH) net sales $345M (+9% YoY), Epidiolex $218M (+10% YoY). IH patient growth 39% YoY, IH market expansion via digital campaigns.
- **Oncology**: Ziihera (BTC) $2M in Q1, Zepzelca facing competition but 1st-line maintenance SNDA submitted. Rylaze $94M (-8% YoY) due to COG protocol changes, expected normalization in Q2.

**【R&D Pipeline Updates】**
- **Zanidatamab**: Phase III GEA trial PFS readout Q3 2025, Phase II data shows 15.2M median PFS vs chemo. ASCO 2025 to present OS data.
- **Dordaviprone**: NDA for recurrent H3K27M-mutant glioma with PDUFA date Aug 18, 2025. Action trial in frontline setting enrolling to plan.
- **JZP441**: Phase IB trial initiated for type 1 narcolepsy.

**【Financial Highlights】**
- GAAP net income: $224M; Non-GAAP EPS: $1.08 (excl. $172M litigation charge).
- 2025 guidance: $4.15B-$4.4B revenue (5% YoY growth), adjusted net income $250M-$350M.
- Tariff mitigation: U.S. manufacturing capacity for Xywav, sufficient inventory to cover 2025 needs.

**【Q&A Key Takeaways】**
- **Supply Chain**: U.S. CMO for Xywav, API sourced domestically to avoid tariffs. 2025 no direct tariff impact, 2026+ scenarios under evaluation.
- **Zepzelca Strategy**: 1st-line maintenance expansion expected to offset 2nd-line competition. ASCO 2025 data to support NCCN guideline inclusion.
- **Dordaviprone Potential**: $890M acquisition cost, $2037 patent expiry. 1st-line trial could extend use beyond recurrent setting.
- **Rylaze Recovery**: AYA market growth offsetting pediatric decline, normalization expected Q2 2025.


Jazz Pharmaceuticals (JAZZ)-6 May 25-2025 Q1 Earnings call transcript

- **Record 2024 Growth**: $4.1B total revenue (+6% YoY), driven by Xywav ($1.5B, +16%), Epidiolex ($972M, +15%), and oncology expansion.
- **Pipeline Momentum**: Ziihera launched in BTC, Zepzelca Phase III data in first-line SCLC expected Q2 2025, and zanidatamab GEA trial readout Q3 2025.
- **Financial Strength**: $1.37B non-GAAP net income in 2024, $3B cash, and 2025 guidance for $4.15-4.4B revenue.
- **Strategic Focus**: M&A in neuroscience/oncology, with $311M share buybacks and debt reduction in 2024.

**【CEO Summary Section】**
- Jazz reported record 2024 revenue of $4.1 billion, up 6% year-over-year, with Q4 revenue of $1.1 billion.
- Key product highlights: Xywav (16% YoY growth to $1.5B), Epidiolex ($972M, +15%), Zepzelca ($320M, +11%), and Ziihera launched in BTC with $1M in Q4 sales.
- R&D milestones included FDA approval of Ziihera for second-line HER2+ BTC and Phase III Zepzelca data in first-line SCLC.
- 2025 guidance: $4.15-4.4B revenue, driven by Xywav, Epidiolex, and oncology growth.

**【CFO Financial Commentary】**
- 2024 non-GAAP net income: $1.37B (EPS $20.90), up 14% YoY.
- 2025 guidance: $1.4-1.5B net income, with $1.25-1.31B SG&A and $720-770M R&D spend.
- Cash flow: $1.4B from operations, $3B cash on hand, and $750M debt repayment in Q1 2024.
- Share buybacks: $311M in 2024, with plans to use free cash flow for debt reduction, buybacks, or M&A.

**【R&D Pipeline Update】**
- Zanidatamab (Ziihera): Phase III GEA trial enrollment complete (918 pts), PFS readout expected H2 2025.
- Zepzelca: sNDA for first-line ES-SCLC maintenance therapy to be filed Q2 2025.
- Orexin-441: Small NT-1 trial ongoing to establish safety margin, no updates yet.

**【Commercial Execution】**
- Xywav maintains #1 narcolepsy share, IH patient adds +350Q4, total Xywav net sales $401M in Q4.
- Epidiolex poised for $1B+ in 2025, with adult LGS and long-term care penetration driving growth.
- Zepzelca maintains leadership in second-line SCLC, with first-line expansion potential post-FDA approval.

**【M&A Strategy】**
- Actively evaluating neuroscience, oncology, and rare disease assets.
- Focus on durability of revenue, commercial infrastructure alignment, and pipeline diversification.
- $3B cash, 1.8x net leverage, and strong cash flow provide flexibility for strategic deals.


Actual												0.45	3.71	4.31	4	3.92	3.9	4.2	4.21	3.73	4.3	5.17	-0.07	3.95	4.51	4.84	5.02	2.68	5.3	6.61	6.6	1.68	-8.25	8.13	6.64
Forecast												0.6386	3.1125	4.0759	4.2376	3.7341	3.5161	3.3185	3.6309	3.84	4.1783	4.6607	0.8829	4.2397	4.4454	4.9325	5.1847	4.1793	4.9221	5.4983	5.8616	4.6576	-7.606	5.9465	6.5176
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-29.53%	+19.20%	+5.74%	-5.61%	+4.98%	+10.92%	+26.56%	+15.95%	-2.86%	+2.91%	+10.93%	-107.93%	-6.83%	+1.45%	-1.88%	-3.18%	-35.87%	+7.68%	+20.22%	+12.60%	-63.93%	-8.47%	+36.72%	+1.88%

JAZZ

JAZZ fundamentals

JAZZ Q4 2025 Earnings

Earnings Call

You can ask Aime

JAZZ

JAZZ fundamentals

JAZZ Q4 2025 Earnings

Earnings Call

JAZZ Earnings Call Summary for Q4/20254:30 PM on Feb 24, 2026

JAZZ Earnings Call Summary for Q3/20254:30 PM on Nov 5, 2025

JAZZ Earnings Call Summary for Q2/20254:30 PM on Aug 5, 2025

JAZZ Earnings Call Summary for Q1/20254:30 PM on May 6, 2025

JAZZ Earnings Call Summary for Q4/20244:30 PM on Feb 25, 2025

You can ask Aime